|
EP3263581B2
(en)
|
2005-05-17 |
2025-07-09 |
University of Connecticut |
Compositions and methods for immunomodulation in an organism
|
|
PL2251034T3
(pl)
|
2005-12-02 |
2018-07-31 |
Icahn School Of Medicine At Mount Sinai |
Chimeryczne wirusy prezentujące nienatywne białka powierzchniowe i zastosowania tych wirusów
|
|
NZ569541A
(en)
|
2006-01-13 |
2012-05-25 |
Us Gov Health & Human Serv |
Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
|
|
CN101743249B
(zh)
|
2007-05-11 |
2017-08-08 |
阿尔托生物科学有限公司 |
融合分子与il‑15变异体
|
|
NZ599338A
(en)
|
2007-06-27 |
2013-11-29 |
Marinepolymer Tech Inc |
Complexes of il-15 and il-15ralpha and uses thereof
|
|
US11053299B2
(en)
|
2010-09-21 |
2021-07-06 |
Immunity Bio, Inc. |
Superkine
|
|
US8507222B2
(en)
*
|
2010-09-21 |
2013-08-13 |
Altor Bioscience Corporation |
Multimeric IL-15 soluble fusion molecules and methods of making and using same
|
|
WO2018112219A1
(en)
*
|
2016-12-14 |
2018-06-21 |
Nant Holdings Ip, Llc |
Superkine
|
|
EP3604339B1
(en)
|
2011-01-14 |
2021-03-10 |
The Regents Of The University Of California |
Therapeutic antibodies against ror-1 protein and methods for use of same
|
|
US9156897B2
(en)
*
|
2012-06-08 |
2015-10-13 |
Alkermes, Inc. |
Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
|
|
US20150359853A1
(en)
|
2012-10-24 |
2015-12-17 |
Admune Therapeutics Llc |
Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
|
|
CA2894511C
(en)
|
2012-12-11 |
2021-12-07 |
Albert Einstein College Of Medicine Of Yeshiva University |
Methods for high throughput receptor:ligand identification
|
|
EP2968525A4
(en)
|
2013-03-14 |
2016-10-26 |
Icahn School Med Mount Sinai |
MORBUS NEWCASTLE VIRUSES AND USES THEREOF
|
|
US11401312B2
(en)
|
2013-04-19 |
2022-08-02 |
Cytune Pharma |
Cytokine derived treatment with reduced vascular leak syndrome
|
|
EP3783098A1
(en)
*
|
2013-05-14 |
2021-02-24 |
Board Of Regents, The University Of Texas System |
Human application of engineered chimeric antigen receptor (car) t-cells
|
|
RS59756B1
(sr)
*
|
2013-08-08 |
2020-02-28 |
Cytune Pharma |
Kombinovana farmaceutska kompozicija
|
|
PT3444271T
(pt)
|
2013-08-08 |
2022-01-05 |
Inst Nat Sante Rech Med |
Modulocinas baseadas em il-15 e no domínio sushi de il-15ralfa
|
|
CA3191031A1
(en)
|
2013-09-27 |
2015-04-02 |
Massachusetts Institute Of Technology |
Carrier-free biologically-active protein nanostructures
|
|
RU2689717C2
(ru)
*
|
2014-01-08 |
2019-05-28 |
Шанхай Хэнжуй Фармасьютикал Ко., Лтд. |
Гетеродимерный белок il-15 и его применения
|
|
PL3094351T3
(pl)
*
|
2014-01-15 |
2022-06-27 |
Kadmon Corporation, Llc |
Środki immunomodulujące
|
|
KR102375998B1
(ko)
|
2014-02-14 |
2022-03-21 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
키메라 항원 수용체 및 제조방법
|
|
EP3110443A4
(en)
|
2014-02-27 |
2017-11-15 |
Viralytics Limited |
Combination method for treatment of cancer
|
|
EP2915569A1
(en)
*
|
2014-03-03 |
2015-09-09 |
Cytune Pharma |
IL-15/IL-15Ralpha based conjugates purification method
|
|
US10464982B2
(en)
|
2014-04-23 |
2019-11-05 |
Emory University |
Compositions of GM-CSF and interleukin fusions for immune modulation and uses related thereto
|
|
DK3143134T3
(da)
*
|
2014-05-15 |
2021-01-04 |
Nat Univ Singapore |
Modificerede, naturlige dræberceller og anvendelser deraf
|
|
KR102762243B1
(ko)
*
|
2014-06-30 |
2025-02-05 |
알토 바이오사이언스 엘엘씨 |
Il-15-베이즈드 분자 및 이의 사용 방법
|
|
ES2811974T3
(es)
|
2014-07-29 |
2021-03-15 |
Novartis Ag |
Regímenes de aumento escalonado de la dosis del heterodímero de il-15 e il-15ralfa para tratar afecciones
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
EP4245376A3
(en)
|
2014-10-14 |
2023-12-13 |
Novartis AG |
Antibody molecules to pd-l1 and uses thereof
|
|
EP3221351B1
(en)
*
|
2014-11-19 |
2024-11-13 |
Memorial Sloan-Kettering Cancer Center |
Methods and compositions for cancer treating conditions relating to over expressions of epha2
|
|
PL3235830T3
(pl)
*
|
2014-12-19 |
2020-12-14 |
Jiangsu Hengrui Medicine Co., Ltd. |
Kompleks białkowy interleukiny 15 i jego zastosowanie
|
|
CN104830884A
(zh)
*
|
2015-01-22 |
2015-08-12 |
苏州大学 |
一种携带IL-15/sIL-15Ra融合基因的微环DNA表达载体的构建方法
|
|
EP3064507A1
(en)
|
2015-03-06 |
2016-09-07 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Fusion proteins comprising a binding protein and an interleukin-15 polypeptide having a reduced affinity for IL15ra and therapeutic uses thereof
|
|
EP3307783B1
(en)
|
2015-06-10 |
2021-01-06 |
Emory University |
Compositions and conjugates comprising an interleukin and polypeptides that specifically bind tgf-beta
|
|
CN112574316A
(zh)
*
|
2015-07-02 |
2021-03-30 |
博际生物医药科技(杭州)有限公司 |
用于肿瘤靶向治疗的白细胞介素-15融合蛋白
|
|
HRP20211058T8
(hr)
|
2015-07-29 |
2021-11-26 |
Novartis Ag |
Kombinirane terapije koje sadrže molekule antitijela protiv lag-3
|
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
|
WO2017027843A1
(en)
|
2015-08-12 |
2017-02-16 |
Massachusetts Institute Of Technology |
Cell surface coupling of nanoparticles
|
|
JP2018532729A
(ja)
*
|
2015-09-25 |
2018-11-08 |
アルター・バイオサイエンス・コーポレーション |
インターロイキン−１５スーパーアゴニストは、移植片対腫瘍活性を大幅に増強する
|
|
MX389194B
(es)
|
2015-10-06 |
2025-03-20 |
Univ Minnesota |
Compuestos terapéuticos y métodos.
|
|
ES2986067T3
(es)
|
2015-12-17 |
2024-11-08 |
Novartis Ag |
Moléculas de anticuerpos frente a PD-1 y usos de las mismas
|
|
WO2017143092A1
(en)
|
2016-02-19 |
2017-08-24 |
Nant Holdings Ip, Llc |
Methods of immunogenic modulation
|
|
WO2017201210A1
(en)
|
2016-05-18 |
2017-11-23 |
Cue Biopharma, Inc. |
T-cell modulatory multimeric polypeptides and methods of use thereof
|
|
CN109689096A
(zh)
|
2016-05-18 |
2019-04-26 |
阿尔伯特爱因斯坦医学院公司 |
变体pd-l1多肽、t细胞调节性多聚体多肽及其使用方法
|
|
JP2019519516A
(ja)
|
2016-05-18 |
2019-07-11 |
モデルナティーエックス， インコーポレイテッド |
がんの治療のためのｍＲＮＡ併用療法
|
|
US10865230B2
(en)
|
2016-05-27 |
2020-12-15 |
Altor Bioscience, Llc |
Construction and characterization of multimeric IL-15-based molecules with CD3 binding domains
|
|
CN109715196A
(zh)
*
|
2016-06-13 |
2019-05-03 |
转矩医疗股份有限公司 |
用于促进免疫细胞功能的组合物和方法
|
|
US20190297861A1
(en)
*
|
2016-07-12 |
2019-10-03 |
Kymab Limited |
Animals, cells, ligands, polypeptides & methods
|
|
US12186342B2
(en)
|
2016-09-23 |
2025-01-07 |
The Regents Of The University Of California |
Autologous irradiated whole cell tumor vaccines lentivirally engineered to express CD80, IL-15 and IL-15 receptor alpha
|
|
MY203000A
(en)
*
|
2016-10-14 |
2024-06-01 |
Xencor Inc |
Il15/il15r� heterodimeric fc-fusion proteins
|
|
WO2018073365A1
(en)
*
|
2016-10-19 |
2018-04-26 |
F. Hoffmann-La Roche Ag |
Method for producing an immunoconjugate
|
|
EP4613776A3
(en)
|
2016-10-21 |
2025-11-26 |
Altor BioScience Corporation |
Multimeric il-15-based molecules
|
|
ES2973548T3
(es)
|
2016-12-22 |
2024-06-20 |
Cue Biopharma Inc |
Polipéptidos multiméricos moduladores de linfocitos T y métodos para su uso
|
|
CN108250301A
(zh)
*
|
2016-12-29 |
2018-07-06 |
天津天锐生物科技有限公司 |
一种多靶点嵌合抗原受体
|
|
CN108250302A
(zh)
|
2016-12-29 |
2018-07-06 |
天津天锐生物科技有限公司 |
一种多功能蛋白质
|
|
EP3565829A4
(en)
|
2017-01-09 |
2021-01-27 |
Cue Biopharma, Inc. |
T-CELL-MODULATING MULTIMERIC POLYPEPTIDES AND METHOD OF USING THEREOF
|
|
WO2018134784A1
(en)
|
2017-01-20 |
2018-07-26 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
|
WO2018134782A1
(en)
|
2017-01-20 |
2018-07-26 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
|
KR102746901B1
(ko)
|
2017-03-03 |
2024-12-26 |
옵시디안 테라퓨틱스, 인크. |
Cd19 조성물 및 면역요법을 위한 방법
|
|
KR102867975B1
(ko)
*
|
2017-03-06 |
2025-10-14 |
알토 바이오사이언스 엘엘씨 |
Il-12 및 il-18로의 il-15-기반 융합
|
|
US20200010528A1
(en)
|
2017-03-15 |
2020-01-09 |
Cue Biopharma, Inc. |
Methods for modulating an immune response
|
|
CA3056591A1
(en)
|
2017-03-27 |
2018-10-04 |
National University Of Singapore |
Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
|
|
BR112019019917A2
(pt)
|
2017-03-27 |
2020-04-22 |
Nat Univ Singapore |
receptores quiméricos nkg2d truncados e seus usos em imunoterapia de células exterminadoras naturais
|
|
US20190048055A1
(en)
|
2017-03-31 |
2019-02-14 |
Altor Bioscience Corporation |
Alt-803 in combination with anti-cd38 antibody for cancer therapies
|
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
|
WO2018229706A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Combination therapy for the treatment of cancer
|
|
US20200121720A1
(en)
|
2017-06-20 |
2020-04-23 |
Nantkwest, Inc. |
Nk-92 cells and il-15 agonist combination therapy
|
|
CA3287539A1
(en)
|
2017-06-21 |
2026-03-02 |
Icell Gene Therapeutics Llc |
CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
|
|
WO2019006472A1
(en)
|
2017-06-30 |
2019-01-03 |
Xencor, Inc. |
TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
|
|
JP2020530280A
(ja)
*
|
2017-07-03 |
2020-10-22 |
トルク セラピューティクス， インコーポレイテッド |
免疫刺激性融合分子およびその使用
|
|
WO2019019998A1
(zh)
|
2017-07-25 |
2019-01-31 |
江苏恒瑞医药股份有限公司 |
一种il-15蛋白复合物药物组合物及其用途
|
|
JP2020533971A
(ja)
|
2017-08-28 |
2020-11-26 |
アルター・バイオサイエンス・コーポレーション |
Ｉｌ−１５をベースとするｉｌ−７及びｉｌ−２１への融合物
|
|
CA3074826A1
(en)
|
2017-09-05 |
2019-03-14 |
Torque Therapeutics, Inc. |
Therapeutic protein compositions and methods of making and using the same
|
|
CN117721084A
(zh)
|
2017-10-12 |
2024-03-19 |
美商生物细胞基因治疗有限公司 |
靶向多种抗原的复合嵌合抗原受体（cCAR）及其组成和使用方法
|
|
CN109705211B
(zh)
|
2017-10-26 |
2020-08-18 |
苏州复融生物技术有限公司 |
一种IgG1 Fc单体及其应用
|
|
WO2019108065A1
(en)
|
2017-12-01 |
2019-06-06 |
Merus N.V. |
Use of bispecific antibody and il-15 for combination therapy
|
|
CA3086040A1
(en)
|
2017-12-19 |
2019-06-27 |
Blaze Bioscience, Inc. |
Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof
|
|
WO2019135958A2
(en)
|
2018-01-05 |
2019-07-11 |
Oleg Shikhman |
Surgical clip and deployment system
|
|
CN111886241A
(zh)
|
2018-01-09 |
2020-11-03 |
库尔生物制药有限公司 |
多聚体t细胞调节多肽及其使用方法
|
|
WO2019150310A1
(en)
|
2018-02-02 |
2019-08-08 |
Novartis Ag |
Combination of sting agonist and il-15/il15-ra for the treatment of cancer
|
|
EP3749685A4
(en)
|
2018-02-09 |
2021-12-22 |
National University of Singapore |
ACTIVATOR CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLING CELL IMMUNOTHERAPY
|
|
CN112004547A
(zh)
|
2018-02-26 |
2020-11-27 |
新索思股份有限公司 |
Il-15缀合物及其用途
|
|
AU2019228381B2
(en)
|
2018-02-28 |
2021-12-16 |
Pfizer Inc. |
IL-15 variants and uses thereof
|
|
US11168138B2
(en)
|
2018-03-26 |
2021-11-09 |
Altor Bioscience, Llc |
Anti-PDL1, IL-15 and TGF-beta receptor combination molecules
|
|
JP7334985B2
(ja)
|
2018-04-02 |
2023-08-29 |
ナショナル ユニヴァーシティー オブ シンガポール |
免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
|
|
WO2019195420A1
(en)
|
2018-04-04 |
2019-10-10 |
Nant Holding IP, LLC |
Advanced avartar dendritic cells
|
|
EP3781598A1
(en)
|
2018-04-18 |
2021-02-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
|
MA52289A
(fr)
|
2018-04-18 |
2021-02-24 |
Xencor Inc |
Protéines de fusion fc hétérodimères il-15/il-15ra et leurs utilisations
|
|
WO2019204646A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
|
|
SG11202010163QA
(en)
|
2018-04-18 |
2020-11-27 |
Xencor Inc |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
US11559044B2
(en)
|
2018-04-26 |
2023-01-24 |
Hoffmann-La Roche Inc. |
Method of and system for tracking an animal in a population of animals
|
|
CN110437339B
(zh)
|
2018-05-04 |
2021-08-13 |
免疫靶向有限公司 |
一种以白介素15为活性成分的融合蛋白型药物前体
|
|
WO2019241315A1
(en)
|
2018-06-12 |
2019-12-19 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
EP3810171B1
(en)
*
|
2018-06-22 |
2025-07-09 |
Cugene Inc. |
Novel interleukin-15 (1l-15) fusion proteins and uses thereof
|
|
AU2019288484B2
(en)
|
2018-06-22 |
2024-06-20 |
Cugene Inc. |
Cytokine-based bioactivatable drugs and methods of uses thereof
|
|
CA3102641A1
(en)
*
|
2018-06-22 |
2019-12-26 |
Kite Pharma, Inc. |
Chimeric transmembrane proteins and uses thereof
|
|
WO2020023713A1
(en)
*
|
2018-07-26 |
2020-01-30 |
Nantbio, Inc. |
Tri-cytokine txm compositions and methods
|
|
CN112513276B
(zh)
|
2018-07-30 |
2024-03-15 |
张晋宇 |
蛋白质异二聚体及其用途
|
|
WO2020037120A1
(en)
*
|
2018-08-16 |
2020-02-20 |
Nantbio, Inc. |
Il7-il15 txm compositions and methods
|
|
WO2020037215A1
(en)
|
2018-08-17 |
2020-02-20 |
Icahn School Of Medicine At Mount Sinai |
Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
|
|
EP3844186A4
(en)
|
2018-08-29 |
2022-08-17 |
National University of Singapore |
METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
|
|
CN112996805A
(zh)
*
|
2018-08-30 |
2021-06-18 |
Hcw生物科技公司 |
多链嵌合多肽和其用途
|
|
EP3843788A1
(en)
|
2018-08-30 |
2021-07-07 |
HCW Biologics, Inc. |
Single-chain chimeric polypeptides and uses thereof
|
|
CN120365435A
(zh)
|
2018-08-30 |
2025-07-25 |
免疫生物公司 |
单链嵌合多肽和多链嵌合多肽以及其用途
|
|
US20220002370A1
(en)
|
2018-09-27 |
2022-01-06 |
Xilio Development, Inc. |
Masked cytokine polypeptides
|
|
WO2020077180A1
(en)
*
|
2018-10-11 |
2020-04-16 |
Nantcell, Inc. |
Treatment of immunosuppressed subjects
|
|
AU2019359475A1
(en)
|
2018-10-12 |
2021-05-20 |
Xencor, Inc. |
PD-1 targeted IL-15/IL-15Ralpha Fc fusion proteins and uses in combination therapies thereof
|
|
CN112912400B
(zh)
|
2018-10-19 |
2025-05-30 |
明尼苏达大学董事会 |
Nk接合子分子及其使用方法
|
|
WO2020097395A1
(en)
|
2018-11-08 |
2020-05-14 |
The Regents Of The University Of California |
Systems and methods for targeting cancer cells
|
|
CA3120563A1
(en)
|
2018-11-26 |
2020-06-04 |
Nkarta, Inc. |
Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
|
|
EP3896089A4
(en)
|
2018-12-13 |
2022-09-07 |
Jiangsu Hengrui Medicine Co., Ltd. |
USE OF IL-15 PROTEIN COMPLEXES IN CONJUNCTION WITH PD-L1 ANTIBODIES FOR THE TREATMENT OF TUMOR DISEASES
|
|
US11873338B2
(en)
|
2018-12-20 |
2024-01-16 |
Merus N.V. |
CLEC12AxCD3 bispecific antibodies and methods for the treatment of disease
|
|
CN113438961A
(zh)
|
2018-12-20 |
2021-09-24 |
Xencor股份有限公司 |
含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白
|
|
AU2020206269A1
(en)
|
2019-01-11 |
2021-08-05 |
Memorial Sloan Kettering Cancer Center |
Multimerization of IL-15/IL-15R-alpha-Fc complexes to enhance immunotherapy
|
|
US12325734B2
(en)
|
2019-01-15 |
2025-06-10 |
Altor Bioscience Llc |
Human immunodeficiency virus-specific T cell receptors
|
|
EP3773918A4
(en)
|
2019-03-05 |
2022-01-05 |
Nkarta, Inc. |
CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
|
|
WO2020231855A1
(en)
|
2019-05-10 |
2020-11-19 |
Nant Holdings Ip, Llc |
Nogapendekin alfa-inbakicept for immune stimulant therapies and treatment of viral infections
|
|
US12085571B2
(en)
|
2019-06-13 |
2024-09-10 |
Immunitybio, Inc. |
Biological deposit labeling and tracking including isotope, rare earth metal or mitochondria tags
|
|
JP7713393B2
(ja)
|
2019-06-21 |
2025-07-25 |
イミュニティーバイオ インコーポレイテッド |
多鎖キメラポリペプチドおよびその使用
|
|
AU2019456283B2
(en)
|
2019-07-08 |
2023-06-08 |
Immunitybio, Inc. |
Mononuclear cell derived NK cells
|
|
US11453862B2
(en)
|
2019-07-08 |
2022-09-27 |
Immunitybio, Inc. |
Mononuclear cell derived NK cells
|
|
US11364291B1
(en)
*
|
2019-07-18 |
2022-06-21 |
Nantcell, Inc. |
Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancer
|
|
CN110478474B
(zh)
*
|
2019-08-21 |
2020-06-02 |
启辰生生物科技(珠海)有限公司 |
免疫调节剂、疫苗、细胞及应用
|
|
US20210061871A1
(en)
*
|
2019-08-29 |
2021-03-04 |
Nantbio, Inc. |
Modified N-810 and Methods Therefor
|
|
US20230092895A1
(en)
|
2019-08-30 |
2023-03-23 |
Obsidian Therapeutics, Inc. |
Tandem cd19 car-based compositions and methods for immunotherapy
|
|
RU2753282C2
(ru)
*
|
2019-09-19 |
2021-08-12 |
Закрытое Акционерное Общество "Биокад" |
ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
|
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
|
WO2021113577A1
(en)
*
|
2019-12-05 |
2021-06-10 |
Immune Targeting Inc. |
Interleukin 15 fusion proteins and prodrugs, and compositions and methods thereof
|
|
CN113135996A
(zh)
*
|
2019-12-09 |
2021-07-20 |
启愈生物技术(上海)有限公司 |
一种双特异抗体及其应用
|
|
CA3165514A1
(en)
*
|
2019-12-31 |
2021-07-08 |
Navrogen, Inc. |
Composition and use of engineered anti-cd20 monoclonal antibodies refactory to tumor immune-suppressive factor ca125/muc16
|
|
WO2021142376A1
(en)
|
2020-01-08 |
2021-07-15 |
Obsidian Therapeutics, Inc. |
Compositions and methods for tunable regulation of transcription
|
|
WO2021142476A1
(en)
*
|
2020-01-12 |
2021-07-15 |
Dragonfly Therapeutics, Inc. |
Single-chain polypeptides
|
|
WO2021155181A1
(en)
*
|
2020-01-31 |
2021-08-05 |
Auragent Bioscience, Llc |
Ultrabright fluorescent nanocomposite structures for enhanced fluorescent bioassays
|
|
US20210244821A1
(en)
|
2020-02-05 |
2021-08-12 |
Novartis Ag |
Cho cell expressed het il-15
|
|
US12115191B2
(en)
|
2020-02-11 |
2024-10-15 |
Immunitybio, Inc. |
Methods of treating age-related and inflammatory diseases
|
|
KR20220140535A
(ko)
|
2020-02-11 |
2022-10-18 |
에이치씨더블유 바이올로직스, 인크. |
크로마토그래피 수지 및 이의 용도
|
|
EP4103599A1
(en)
|
2020-02-11 |
2022-12-21 |
HCW Biologics, Inc. |
Methods of activating regulatory t cells
|
|
CN115244077B
(zh)
|
2020-03-11 |
2025-04-29 |
南特细胞公司 |
蛋白质治疗剂
|
|
WO2021202354A1
(en)
*
|
2020-03-30 |
2021-10-07 |
Proviva Therapeutics (Hong Kong) Limited |
Il-2/il-15 compositions and methods of use thereof
|
|
TW202214290A
(zh)
|
2020-04-22 |
2022-04-16 |
瑞士商諾華公司 |
異源二聚體人介白素－１５（ｈｅｔｉｌ－１５）之藥物組成物及藥物產品
|
|
EP4143231A1
(en)
|
2020-04-29 |
2023-03-08 |
HCW Biologics, Inc. |
Anti-cd26 proteins and uses thereof
|
|
WO2021231376A2
(en)
|
2020-05-12 |
2021-11-18 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
US11318189B1
(en)
|
2020-05-13 |
2022-05-03 |
Nantcell, Inc. |
IL-15 agonist drug combinations for immune therapy
|
|
US12024545B2
(en)
|
2020-06-01 |
2024-07-02 |
HCW Biologics, Inc. |
Methods of treating aging-related disorders
|
|
US20230226203A1
(en)
*
|
2020-06-18 |
2023-07-20 |
Proviva Therapeutics (Hong Kong) Limited |
Activatable procytokines
|
|
US12252525B2
(en)
|
2020-07-31 |
2025-03-18 |
Nantbio, Inc. |
Chimeric T cell receptors, nucleic acids, and methods of making and using the same
|
|
KR102863510B1
(ko)
*
|
2020-08-03 |
2025-09-23 |
난트셀, 인크. |
Il-15 초작용제에 대한 약물-특이적 약동학 검정 (drug-specific pharmacokinetic assay for il-15 superagonist cross-reference to related applications)
|
|
WO2022056014A1
(en)
|
2020-09-09 |
2022-03-17 |
Cue Biopharma, Inc. |
Mhc class ii t-cell modulatory multimeric polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
|
|
JP2023540629A
(ja)
*
|
2020-09-16 |
2023-09-25 |
ベイジーン リミテッド |
インターロイキン１５構築物及び使用方法
|
|
WO2022115865A2
(en)
|
2020-11-25 |
2022-06-02 |
Xilio Development, Inc. |
Tumor-specific cleavable linkers
|
|
US11459372B2
(en)
|
2020-11-30 |
2022-10-04 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
KR20230118887A
(ko)
|
2020-12-03 |
2023-08-14 |
센츄리 쎄라퓨틱스 인코포레이티드 |
유전자 조작 세포 및 이의 용도
|
|
AR124414A1
(es)
|
2020-12-18 |
2023-03-22 |
Century Therapeutics Inc |
Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
|
|
US20240117002A1
(en)
*
|
2020-12-23 |
2024-04-11 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
WO2022144632A1
(en)
|
2020-12-30 |
2022-07-07 |
Crispr Therapeutics Ag |
Compositions and methods for differentiating stem cells into nk cells
|
|
CN113321736B
(zh)
*
|
2020-12-30 |
2024-01-09 |
苏州复融生物技术有限公司 |
一种长效化白介素15融合蛋白及其制备方法和应用
|
|
WO2022165260A1
(en)
|
2021-01-29 |
2022-08-04 |
Iovance Biotherapeutics, Inc. |
Methods of making modified tumor infiltrating lymphocytes and their use in adoptive cell therapy
|
|
MX2023011268A
(es)
|
2021-03-24 |
2023-12-14 |
Alkermes Inc |
Anticuerpos upar y proteínas de fusión con estos.
|
|
JP2024512714A
(ja)
*
|
2021-03-31 |
2024-03-19 |
アンウィタ バイオサイエンシス， インク． |
融合タンパク質、医薬組成物、及び治療適用
|
|
US20250197525A1
(en)
|
2021-04-28 |
2025-06-19 |
Minotaur Therapeutics, Inc. |
Humanized chimeric bovine antibodies and methods of use
|
|
CN113321740B
(zh)
*
|
2021-05-08 |
2023-07-18 |
上海交通大学 |
一种融合蛋白及其制备方法和用途
|
|
CA3220027A1
(en)
*
|
2021-05-28 |
2022-12-01 |
Amato J. Giaccia |
Bispecific fc fusion proteins with spd-1 and il-15
|
|
WO2022260849A1
(en)
|
2021-06-09 |
2022-12-15 |
Nant Holdings Ip, Llc |
Methods and systems for producing a protein of interest in a plant
|
|
CN113736810B
(zh)
*
|
2021-09-08 |
2024-05-24 |
苏州因特药物研发有限公司 |
构建体、载体、蛋白、细胞、制备方法、产品及应用
|
|
US20240415964A1
(en)
|
2021-11-02 |
2024-12-19 |
Immunitybio, Inc. |
Natural killer cells for chordoma therapy
|
|
US20230151095A1
(en)
|
2021-11-12 |
2023-05-18 |
Xencor, Inc. |
Bispecific antibodies that bind to b7h3 and nkg2d
|
|
KR20240131446A
(ko)
|
2022-01-22 |
2024-08-30 |
난트셀, 인크. |
Ctla4 및 il-15의 융합 분자
|
|
EP4507711A1
(en)
|
2022-04-13 |
2025-02-19 |
ImmunityBio, Inc. |
Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder
|
|
CN116854821A
(zh)
|
2022-08-15 |
2023-10-10 |
海徕科(北京)生物技术有限公司 |
IL-15突变体-Fc/IL-15Rα亚基-Fc异源二聚体及其用途
|
|
EP4335870A1
(en)
|
2022-09-06 |
2024-03-13 |
NantCell, Inc. |
Peptide therapeutics against sars-cov-2 spike protein
|
|
WO2024102636A1
(en)
|
2022-11-07 |
2024-05-16 |
Xencor, Inc. |
Bispecific antibodies that bind to b7h3 and mica/b
|
|
WO2024118836A1
(en)
|
2022-11-30 |
2024-06-06 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes with shortened rep step
|
|
CN120916753A
(zh)
*
|
2023-03-29 |
2025-11-07 |
星锐医药(苏州)有限公司 |
编码治疗性多肽的核酸及包含所述核酸的脂质纳米颗粒组合物
|
|
EP4724099A2
(en)
*
|
2023-06-06 |
2026-04-15 |
Jecho Laboratories, Inc. |
Interleukin-15 fusion protein and methods of use
|
|
WO2025010111A1
(en)
*
|
2023-07-05 |
2025-01-09 |
Nanotein Technologies, Inc. |
Cell signaling complexes and uses thereof
|
|
WO2025015318A2
(en)
|
2023-07-13 |
2025-01-16 |
Iovance Biotherapeutics, Inc. |
Cytokine encoding lentiviral vectors and uses thereof for making tumor infiltrating lymphocytes
|
|
US12473529B2
(en)
|
2023-07-18 |
2025-11-18 |
Nanotein Technologies, Inc. |
Reagents, reagent kits, and culture media for activating and expanding immune cells and uses thereof
|
|
AU2024354387A1
(en)
*
|
2023-10-02 |
2026-02-05 |
Immunitybio, Inc. |
Methods of generating, stimulating, or increasing proliferation of different subsets of cd8+ t cells
|
|
WO2025085672A1
(en)
|
2023-10-17 |
2025-04-24 |
Xencor, Inc. |
Bispecific antibodies that bind to nkp46 and mica/b
|
|
US20250134974A1
(en)
*
|
2023-10-31 |
2025-05-01 |
Immunitybio, Inc. |
Multi-chain chimeric polypeptides and use thereof in the treatment of advanced solid tumors
|
|
CN118108809B
(zh)
*
|
2024-03-15 |
2025-02-28 |
西湖实验室(生命科学和生物医学浙江省实验室) |
一种跨膜荧光蛋白、水溶荧光蛋白及其用途
|
|
WO2026006784A1
(en)
|
2024-06-28 |
2026-01-02 |
Iovance Biotherapeutics, Inc. |
Methods of making tumor reactive peripheral blood lymphocytes (trpbl)
|
|
WO2026006370A1
(en)
|
2024-06-28 |
2026-01-02 |
Immunitybio, Inc. |
Anti-slamf7 antibodies and therapeutics
|
|
WO2026024752A1
(en)
|
2024-07-23 |
2026-01-29 |
Immunitybio, Inc. |
Compositions and methods related to potent cytotoxic m-cenk cells from cd3/cd14-depleted apheresis products
|